JP2010518020A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518020A5
JP2010518020A5 JP2009548460A JP2009548460A JP2010518020A5 JP 2010518020 A5 JP2010518020 A5 JP 2010518020A5 JP 2009548460 A JP2009548460 A JP 2009548460A JP 2009548460 A JP2009548460 A JP 2009548460A JP 2010518020 A5 JP2010518020 A5 JP 2010518020A5
Authority
JP
Japan
Prior art keywords
rab
doc
antigen
coh
cohesin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548460A
Other languages
English (en)
Japanese (ja)
Other versions
JP5543785B2 (ja
JP2010518020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/052714 external-priority patent/WO2008097817A2/en
Publication of JP2010518020A publication Critical patent/JP2010518020A/ja
Publication of JP2010518020A5 publication Critical patent/JP2010518020A5/ja
Application granted granted Critical
Publication of JP5543785B2 publication Critical patent/JP5543785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548460A 2007-02-02 2008-01-31 ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原 Expired - Fee Related JP5543785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88802907P 2007-02-02 2007-02-02
US60/888,029 2007-02-02
PCT/US2008/052714 WO2008097817A2 (en) 2007-02-02 2008-01-31 Multivariable antigens complexed with targeting humanized monoclonal antibody

Publications (3)

Publication Number Publication Date
JP2010518020A JP2010518020A (ja) 2010-05-27
JP2010518020A5 true JP2010518020A5 (enExample) 2011-03-17
JP5543785B2 JP5543785B2 (ja) 2014-07-09

Family

ID=39682338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009548460A Expired - Fee Related JP5543785B2 (ja) 2007-02-02 2008-01-31 ヒト化ターゲティングモノクローナル抗体と複合体を形成する複数の可変抗原

Country Status (16)

Country Link
US (3) US7786267B2 (enExample)
EP (2) EP2684889A3 (enExample)
JP (1) JP5543785B2 (enExample)
KR (1) KR20090114425A (enExample)
CN (1) CN101657464A (enExample)
AU (1) AU2008214077B2 (enExample)
BR (1) BRPI0807344A2 (enExample)
CA (1) CA2715042C (enExample)
DK (1) DK2114985T3 (enExample)
ES (1) ES2536900T3 (enExample)
IL (1) IL200092A0 (enExample)
MX (1) MX2009008143A (enExample)
NZ (2) NZ592859A (enExample)
TW (1) TW200846371A (enExample)
WO (1) WO2008097817A2 (enExample)
ZA (1) ZA200905447B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
CN101657464A (zh) * 2007-02-02 2010-02-24 贝勒研究院 与靶向人源化单克隆抗体复合的多变量抗原
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
NZ595319A (en) * 2007-02-23 2012-09-28 Baylor Res Inst Activation of human antigen-presenting cells through clec-6
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
EP2307443B1 (en) * 2008-08-07 2013-10-02 Yeda Research And Development Company Ltd. Affinity purification by cohesin-dockerin interaction
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
DK2406289T3 (en) * 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
US9097713B2 (en) * 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
EP2477655A4 (en) 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
BR112012028522A2 (pt) * 2010-05-07 2016-07-19 Baylor Res Inst sensibilização cruzada mediada por imunorreceptores de células dendríticas (dcir) de células t humanas cd8+
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
AR088428A1 (es) * 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
WO2013033104A1 (en) * 2011-08-29 2013-03-07 Baylor Research Institute CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR DECTIN-1 AND TOLL-LIKE RECEPTOR 2 (TLR2)
MX354902B (es) * 2011-11-23 2018-03-23 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos.
CA2875783C (en) * 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
CN103044552B (zh) * 2012-12-11 2019-01-29 中国医学科学院病原生物学研究所 人源化的抗树突状细胞表面dec-205分子的单克隆抗体
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
CN105555303A (zh) 2013-06-28 2016-05-04 贝勒研究院 用于多发性硬化症的树突细胞asgpr靶向免疫治疗剂
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
EP3253799B1 (en) * 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3424538A1 (en) * 2017-07-06 2019-01-09 Centre National De La Recherche Scientifique Bioconjugates with a controlled degree of conjugation, their process of preparation, and the reagents for their preparation
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
IL263409B2 (en) 2018-12-02 2023-06-01 Linet Spol Sro Detection of tiny movement in the human body
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CN110790836A (zh) * 2019-11-22 2020-02-14 郑州安图生物工程股份有限公司 一种人抑制素b的单克隆抗体及其应用和试剂盒
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
MX2022014943A (es) 2020-05-26 2023-03-08 Inst Nat Sante Rech Med Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
MX2023005570A (es) 2020-11-12 2023-05-29 Inst Nat Sante Rech Med Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
EP4267176A1 (en) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
US20240124532A1 (en) 2021-01-29 2024-04-18 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
WO2023088968A1 (en) 2021-11-17 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Universal sarbecovirus vaccines
WO2024074571A1 (en) 2022-10-05 2024-04-11 Institut National de la Santé et de la Recherche Médicale Dc-targeting vaccine against nipah virus infection

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) * 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
AU726108B2 (en) 1995-10-17 2000-11-02 Genencor International, Inc. Enzymatic array and process of making same
FR2748479A1 (fr) * 1996-05-10 1997-11-14 Pasteur Institut Polypeptide comportant un nouveau domaine cohesine de type ii, composition enzymatique en comportant et fragments d'adn codant pour ces polypeptides
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
JP2000157282A (ja) * 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
EP1165813A2 (en) * 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Linear and circular expression elements
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2408547A1 (en) * 2000-05-11 2001-11-15 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
US20050106700A1 (en) * 2001-10-11 2005-05-19 Tsuyoshi Nomura Method of purifying recombinant fused protein and method of producing protein using the same
JP2004236504A (ja) * 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
US20050064509A1 (en) * 2003-09-23 2005-03-24 The Regents Of The University Of California Use of templated self assembly to create novel multifunctional species
WO2005058244A2 (en) * 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
TWI422594B (zh) * 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
CN101657464A (zh) * 2007-02-02 2010-02-24 贝勒研究院 与靶向人源化单克隆抗体复合的多变量抗原
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신

Similar Documents

Publication Publication Date Title
JP2010518020A5 (enExample)
CN112534052B (zh) 全新il-21前药及使用方法
JP2010517538A5 (enExample)
JP2021502810A5 (enExample)
Ahmed et al. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
AU2008214036B2 (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (DC- ASGPR)
US6979726B1 (en) Immunoconjugates
WO2019129053A1 (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
JP2010536386A5 (enExample)
JP2022523333A5 (enExample)
CN103833852A (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
RU2009123409A (ru) Новые антипролиферативные антитела
JP2007181458A (ja) 組み換え三重足場ベースポリペプチド
De Jonge et al. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3× anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model
Zekri et al. Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies
WO2001079494A1 (fr) Anticorps agonistes
JP2025505434A5 (enExample)
Dreier et al. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities
CA2463616A1 (en) Affinity enhancement agents
US12264189B2 (en) Methods and materials for treating cancer
Saleh et al. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma
WO2025011540A1 (zh) 一种抗体Fab片段的二聚体、其制备方法及应用
Paul et al. Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies
Waldmann Lymphokine receptors: a target for immunotherapy of lymphomas
WO2022178163A2 (en) Antibody-derived t cell activating technologies